6853-57-2

Usage

Uses

Used in Fragrance Industry:
4-N-Pentylbenzaldehyde is used as a fragrance ingredient for its pleasant, sweet, and floral scent. It is incorporated into various perfumes, colognes, and other scented products to enhance their aroma profile and provide a unique olfactory experience.
Used in Flavor Industry:
In the flavor industry, 4-N-Pentylbenzaldehyde is utilized as a flavoring agent to impart a subtle sweetness and floral note to food and beverage products. It is commonly found in the formulation of beverages, confectionery, and other edible items to create a more complex and appealing taste.
Used in Chemical Synthesis:
4-N-Pentylbenzaldehyde serves as a key intermediate in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals. Its unique structure allows for further functionalization and modification, making it a versatile building block in organic chemistry.
Used in Research and Development:
Due to its distinctive chemical properties and potential applications, 4-N-Pentylbenzaldehyde is often employed in research and development settings. Scientists and researchers use 4-N-PENTYLBENZALDEHYDE to explore new reactions, investigate its biological activities, and develop innovative applications in various fields, such as materials science, nanotechnology, and environmental science.

InChI:InChI=1/C12H16O/c1-2-3-4-5-11-6-8-12(10-13)9-7-11/h6-10H,2-5H2,1H3

Upstream product

• 79-37-8 oxalyl dichloride 
• 49763-65-7 4-pentylbenzoyl chloride 
• 4885-02-3 Dichloromethyl methyl ether 
• 538-68-1 pentylbenzene 
• 100-97-0 hexamethylenetetramine 
• 81720-37-8 4-n-pentylbenzyl alcohol 
• 93943-06-7 4-(methoxymethyl)benzaldehyde 
• 627-19-0 1-Pentyne 
• 1122-91-4 4-bromo-benzaldehyde 
• 55962-05-5 [N-(p-tolylsulfonyl)imino]phenyliodinane 
• 18869-30-2 (E)-4,4'-dibromostilbene 
• 1809-10-5 3-bromopentane 
• 17763-69-8 4-(trifluormethanesulfonyloxy)benzaldehyde 
• 109-66-0 pentane 

Downstream Products

• 90672-90-5 Isothiazol-5-yl-(4-pentyl-phenyl)-methanol 
• 85017-61-4 trans-β-(n-amyl)acrylic acid 
• 90863-27-7 2,5-Bis-(4-pentyl-phenyl)-[1,3]dioxane 
• 81221-36-5 2,5-Bis-(4-pentyl-phenyl)-[1,3]dioxane 
• 26311-45-5 4-pentylbenzoic acid 
• 81720-37-8 4-n-pentylbenzyl alcohol 
• 284044-50-4 4-n-Pentyl-β,β'-dibromostyrene 
• 596813-62-6 (4-pentylbenzyl)pyridin-3-ylamine 

Relevant academic research and scientific papers

Azole-based non-peptidomimetic plasmepsin inhibitors

The spread of drug-resistant malaria parasites urges the search for new antimalarial drugs. Malarial aspartic proteases – plasmepsins (Plms) – are differentially expressed in multiple stages of the Plasmodium parasite's lifecycle and are considered as attractive drug targets. We report the development of novel azole-based non-peptidomimetic plasmepsin inhibitors that have been designed by bioisosteric substitution of the amide moiety in the Actelion amino-piperazine inhibitors. The best triazole-based inhibitors show submicromolar potency toward Plm II, which is comparable to that of the parent Actelion compounds. The new inhibitors can be used as a starting point for the development of a resistance-free antimalarial drug targeting the non-digestive Plm IX or X, which are essential for the malaria parasite life cycle.

Pd-PEPPSI-IPent-SiO2: A Supported Catalyst for Challenging Negishi Coupling Reactions in Flow

A silica-supported precatalyst, Pd-PEPPSI-IPent-SiO2, has been prepared and evaluated for its proficiency in the Negishi cross-coupling of hindered and electronically deactivated coupling partners. The precatalyst Pd-PEPPSI-IPent loaded onto packed bed columns shows high catalytic activity for the room-temperature coupling of deactivated/hindered biaryl partners. Also for the first time, the flowed Csp3–Csp2 coupling of secondary alkylzinc reagents to (hetero)aromatics has been achieved with high selectivity with Pd-PEPPSI-IPent-SiO2. These couplings required residence times as short as 3 minutes to effect completion of these challenging transformations with excellent selectivity for the nonrearranged product.

SUBSTITUTED AMINOALKYLAZOLES AS MALARIAL ASPARTIC PROTEASE INHIBITORS

The present invention relates to novel aminoalkylazoles acting as inhibitors of malarial protease plasmepsin II. These can be used as medicines or as constituent of medicines for the treatment of malaria infection.

Terminal-Selective Functionalization of Alkyl Chains by Regioconvergent Cross-Coupling

Hydrocarbons are still the most important precursors of functionalized organic molecules, which has stirred interest in the discovery of new C?H bond functionalization methods. We describe herein a new step-economical approach that enables C?C bonds to be constructed at the terminal position of linear alkanes. First, we show that secondary alkyl bromides can undergo in situ conversion into alkyl zinc bromides and regioconvergent Negishi coupling with aryl or alkenyl triflates. The use of a suitable phosphine ligand favoring Pd migration enabled the selective formation of the linear cross-coupling product. Subsequently, mixtures of secondary alkyl bromides were prepared from linear alkanes by standard bromination, and regioconvergent cross-coupling then provided access to the corresponding linear arylation product in only two steps.

Metal-catalyzed formal amidation of alkenes under CO-free condition

An effective procedure for synthesis of amides from alkenes and [Formula presented] via Pd and Fe catalysts under mild conditions is described. A series of benzamides containing various functional groups can be obtained in reasonable yield and the possible reaction pathway is proposed in this Letter.

Antimycobacterial activity evaluation, time-kill kinetic and 3D-QSAR study of C-(3-aminomethyl-cyclohexyl)-methylamine derivatives

A series of C-(3-aminomethyl-cyclohexyl)-methylamine derivatives were synthesized and evaluated for their antitubercular activity. Some of the compounds exhibited potent activity against Mycobacterium tuberculosis H37Rv. One of the compound having t-butyl at para position of the benzene ring showed excellent activity even better than the standard drug ethambutol with MIC value 1.1 ± 0.2 μM. The time-kill kinetics study of two most active compounds showed rapid killing of the M. tuberculosis within 4 days. Additionally atom-based quantitative structure-activity relationship (QSAR) model was developed that gave a statistically satisfying result (R2) = 0.92, Q2 = 0.75, Pearson-R = 0.96 and effectively predicts the anti-tuberculosis activity of training and test set compounds.

ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES

The invention provides compounds of formula la, lb and Ic: [Formula Ia, Ib, and Ic] and salts thereof, wherein variables are as described in the specification, as well as compositions comprising a compound of formula Ia-Ic, methods of making such compounds, and methods of using such compounds, e.g., as inhibitors of bacterial RNA polymerase and as antibacterial agents.

Gold-catalyzed oxidation of arylallenes: Synthesis of quinoxalines and benzimidazoles

A gold-catalyzed oxidation of arylallenes to form α-diketones and aldehydes in good yields is presented. Further directed synthesis of quinoxalines and benzimidazoles, via the condensation of the resulting α-diketones and aldehydes with benzene-1,2-diamine, was achieved in high yields.

Reductive lithiation of 1,3-dimethyl-2-arylimidazolidines

Naphthalene catalyzed lithiation of 1,3-dimethyl-2-phenylimidazolidine led to cleavage of the benzylic carbon-nitrogen bond, with formation of an intermediate dianion. Under similar conditions, 1,3-dimethyl-2-(4-chlorophenyl) imidazolidine underwent regioselective cleavage of the aromatic carbon-chlorine bond, leading to a 4-formylphenyllithium equivalent, whilst 1,3-dimethyl-2-(4- methoxymethylphenyl)imidazolidine underwent regioselective cleavage of the benzylic carbon-oxygen bond, leading to a 4-formylbenzyllithium equivalent.

Development of novel EDG3 antagonists using a 3D database search and their structure-activity relationships

Sphingosine-1-phosphate (S1P) is an intracellular second messenger and an extracellular mediator through endothelial differentiation gene (EDG) receptors, which are a novel class of G-protein-coupled receptors. Although EDG has attracted much attention because of its various roles, no selective agonists or antagonists have yet been developed. This could account for the delay in clarifying the physiological roles of members of the EDG family. Because precise structural information on EDG receptors is not yet available, pharmacophore models were generated based on structural information for S1P using the rational drug design software Catalyst. Novel antagonists, 2-alkylthiazolidine-4-carboxylic acids, were retrieved from a three-dimensional database search using the pharmacophore models, and these showed activity for EDG3. On the basis of their nonphosphoric acid structure, more potent antagonists, 2-(m- or p-heptylphenyl)thiazolidine-4-carboxylic acid, were developed.